Skip Navigation Links
Skip Navigation Links
Centers for Disease Control and Prevention

Hemochromatosis for Health Care Professionals
Topic Index Glossary Resources Bibliography Print-friendly PDF
Home
Pathophysiology
Epidemiology
Prevalence
Summary
Clinical Features
Diagnostic Testing
Treatment & Management
Family-based Detection
Course Summary
Case Studies

Epidemiology
Summary

 
On This Page...
Summary
Test Your Knowledge
 

Prevalence

  • Reported U.S. population prevalence estimates of iron overloading (based on random non-fasting elevated transferrin saturation, TS values) range from 1% to 6%.
  • A lower percentage of people who initially have a random elevated TS also have persistently elevated TS: estimates range from 35% to 50%.
  • An even lower percentage of people with persistently elevated TS measures also have elevated serum ferritin values.
  • Thus, the proportion of people who will develop clinical signs and symptoms of hemochromatosis is even lower than the proportion of people with elevated serum ferritin, SF values.

HFE gene mutations

  • Two HFE gene mutations, C282Y and H63D, account for the majority of hereditary hemochromatosis cases; C282Y is most common.
  • Hereditary hemochromatosis is inherited in an autosomal recessive pattern.

HFE genotype frequencies

  • The population prevalence of HFE mutations depends on race and ethnicity but is most prevalent among persons of European origin and descent.

Penetrance

  • Of people with HFE gene mutations, only a subset will develop an elevated TS. Of those with an elevated TS, only a subset will develop an elevated SF. Of those with an elevated SF, only a subset will develop hemochromatosis symptoms. Of those with symptoms, only a subset will develop clinical signs consistent with hemochromatosis.
  • Most clinicians reserve the hemochromatosis diagnosis for patients whose signs and symptoms are clearly referable to documented iron overload as reflected by serum iron testing measurements.
  • Iron status testing is more clinically relevant than genetic testing for identifying those who have hemochromatosis.

Population screening

  • At this time, CDC does not recommend population screening for HFE gene mutations because of the uncertainty about what proportion of people with HFE gene mutations will develop hemochromatosis.


Test Your Knowledge

This is an optional self-quiz and is not required for continuing education credit.

Select the best answers below. If you need help, feel free to go back to Prevalence and review.

Question 1: Which of the following factors may place a patient at increased risk of developing hemochromatosis?
Select the best answer(s) below:
European origin and descent.
Blood relative with documented iron overload.
Blood relative with a documented HFE gene mutation.
Blood relative with documented hemochromatosis.
Blood relative with documented hereditary hemochromatosis.


Question 2: Of people with HFE gene mutations, only a subset will develop clinical signs consistent with hemochromatosis.
True
False


 
back Prevalence

return to top

 Clinical Features next


 

 

This page last updated November 01, 2007

United States Department of Health and Human Services
Centers for Disease Control and Prevention
National Center for Chronic Disease Prevention and Health Promotion
Division of Nutrition and Physical Activity